• Know-how in isolation of wild phages from natural sources 

  • Proprietary algorithms for the qualitative selection of distinctly lytic and highly virulent phages
  • Patented cost-effective production of purified, high volumes – high titer phages concentrations
  • Proprietary Preservation, Adsorption Promoters and Enhanced-Delivery formulations
  • Expertise in Food, Agriculture, Aquaculture and Fermentation





Production and Application of Bacteriophage and Bacteriophage-Encoded Lysins –Noémie M. Dorval Courchesne, Albert Parisien and Christopher Q. Lan*Department of Chemical and Biological Engineering, The University of Ottawa, Ottawa, ON, K1N 6N5, Canada

Abstract: The widespread resistance to antibiotics among pathogenic bacteria has made development of alternatives to antibiotics a pressing public concern. Extensive studies have established bacteriophages (phages) and phage-encoded lytic enzymes (virolysins) as two of the most promising families of alternative antibacterials for the treatment and prophylaxis of bacterial infections. They have shown great potential in veterinary and human medicine for the treatment and prophylaxis of infections. Technologies have also been patented employing phages and virolysins in other pathogen related applications including detection and decontamination.

Given the fact that phage cocktails are most commonly used in phage therapies, the required total production volumes would be even larger. Therefore, the ability of obtaining high phage titers would be very important to enhance the affordability of phage therapy. A few inventions have been filed disclosing different approaches to increase the efficiency of phage production process. For instance, one invention provides a method for intermediate to large scale commercial production of bacteriophage composition, employing a semi-solid medium containing 0.5% or less hydrocolloid (e.g. agar) to create favourable conditions for phage growth, leading to a high titer of at least 1011 PFU/ml (by Phage Biotech Ltd.)…